AAPL333.69+3.37 (+1.02%) ▲|ABBV262.82+2.89 (+1.11%) ▲|ABT97.50+0.81 (+0.84%) ▲|ACN198.90-13.40 (-6.31%) ▼|ADBE237.69-3.59 (-1.49%) ▼|AMAT540.04+10.74 (+2.03%) ▲|AMD633.91+18.18 (+2.95%) ▲|AMGN403.04-4.23 (-1.04%) ▼|AMT162.20+1.14 (+0.71%) ▲|AMZN251.52+3.29 (+1.33%) ▲|AVGO355.14+11.50 (+3.35%) ▲|AXP302.78+0.69 (+0.23%) ▲|BA193.56+1.28 (+0.67%) ▲|BAC53.75+0.02 (+0.04%) ▲|BKNG159.02-1.26 (-0.79%) ▼|BLK1,059.63-4.73 (-0.44%) ▼|BMY61.15+0.32 (+0.53%) ▲|BNY145.40+1.48 (+1.03%) ▲|BRK-B502.65+2.15 (+0.43%) ▲|C128.50+1.50 (+1.18%) ▲|CAT845.42+19.07 (+2.31%) ▲|CL84.26-0.27 (-0.32%) ▼|CMCSA21.57-0.13 (-0.60%) ▼|COF194.72+0.24 (+0.12%) ▲|COP126.75-0.31 (-0.24%) ▼|COST920.65+5.71 (+0.62%) ▲|CRM234.69-2.00 (-0.85%) ▼|CSCO112.20+3.86 (+3.56%) ▲|CVS86.46+1.26 (+1.48%) ▲|CVX206.69-0.41 (-0.20%) ▼|DE687.00+19.74 (+2.96%) ▲|DHR214.06+2.30 (+1.09%) ▲|DIS102.19+0.86 (+0.85%) ▲|DUK114.13+0.39 (+0.34%) ▲|EMR161.61+3.04 (+1.92%) ▲|FDX290.36+3.29 (+1.15%) ▲|GD330.09-2.63 (-0.79%) ▼|GE309.56-2.83 (-0.91%) ▼|GEV988.70+1.25 (+0.13%) ▲|GILD144.74-2.76 (-1.87%) ▼|GM78.27-1.04 (-1.31%) ▼|GOOG340.35+5.42 (+1.62%) ▲|GOOGL343.50+5.26 (+1.56%) ▲|GS902.56+5.89 (+0.66%) ▲|HD282.85+0.39 (+0.14%) ▲|HON213.99+0.19 (+0.09%) ▲|IBM222.64-2.98 (-1.32%) ▼|INTC119.33-0.67 (-0.56%) ▼|INTU281.08-1.70 (-0.60%) ▼|ISRG391.95-9.29 (-2.32%) ▼|JNJ256.03-2.63 (-1.02%) ▼|JPM332.38-0.80 (-0.24%) ▼|KO85.65-0.45 (-0.52%) ▼|LIN479.48+10.03 (+2.14%) ▲|LLY1,142.85-7.00 (-0.61%) ▼|LMT505.41-0.09 (-0.02%) ▼|LOW180.80-1.58 (-0.87%) ▼|LRCX347.49+7.39 (+2.17%) ▲|MA552.26+2.26 (+0.41%) ▲|MCD231.89+0.06 (+0.03%) ▲|MDLZ58.19+0.43 (+0.74%) ▲|MDT86.38-0.06 (-0.07%) ▼|META728.08+2.15 (+0.30%) ▲|MMM161.89-1.13 (-0.69%) ▼|MO67.35+0.40 (+0.60%) ▲|MRK144.30+0.49 (+0.34%) ▲|MS190.31+2.30 (+1.22%) ▲|MSFT517.53+4.73 (+0.92%) ▲|MU1,074.89-22.50 (-2.05%) ▼|NEE76.83+0.48 (+0.63%) ▲|NFLX67.06-0.79 (-1.16%) ▼|NKE33.87-1.28 (-3.64%) ▼|NOW134.38-3.38 (-2.45%) ▼|NVDA233.95+3.09 (+1.34%) ▲|ORCL142.30+4.23 (+3.06%) ▲|PEP125.89+0.29 (+0.23%) ▲|PFE27.80-0.32 (-1.14%) ▼|PG144.91+0.96 (+0.67%) ▲|PLTR188.75-1.29 (-0.68%) ▼|PM187.46+0.88 (+0.47%) ▲|QCOM184.87+2.78 (+1.53%) ▲|RTX184.68-0.33 (-0.18%) ▼|SBUX94.71-0.17 (-0.18%) ▼|SCHW96.70-1.67 (-1.70%) ▼|SO83.72+0.25 (+0.30%) ▲|SPG200.95+0.14 (+0.07%) ▲|T24.30+0.00 (+0.00%) ▲|TMO654.80+2.29 (+0.35%) ▲|TMUS163.64+1.91 (+1.18%) ▲|TSLA370.59+16.48 (+4.65%) ▲|TXN293.80+12.49 (+4.44%) ▲|UBER68.11+0.23 (+0.34%) ▲|UNH371.90+6.70 (+1.83%) ▲|UNP278.28+5.86 (+2.15%) ▲|UPS93.02-0.87 (-0.93%) ▼|USB57.51+0.15 (+0.26%) ▲|V360.66+0.81 (+0.23%) ▲|VZ45.92-0.06 (-0.13%) ▼|WFC80.45+0.20 (+0.25%) ▲|WMT104.26+0.00 (+0.00%) ▲|XOM164.01+0.19 (+0.12%) ▲|AAPL333.69+3.37 (+1.02%) ▲|ABBV262.82+2.89 (+1.11%) ▲|ABT97.50+0.81 (+0.84%) ▲|ACN198.90-13.40 (-6.31%) ▼|ADBE237.69-3.59 (-1.49%) ▼|AMAT540.04+10.74 (+2.03%) ▲|AMD633.91+18.18 (+2.95%) ▲|AMGN403.04-4.23 (-1.04%) ▼|AMT162.20+1.14 (+0.71%) ▲|AMZN251.52+3.29 (+1.33%) ▲|AVGO355.14+11.50 (+3.35%) ▲|AXP302.78+0.69 (+0.23%) ▲|BA193.56+1.28 (+0.67%) ▲|BAC53.75+0.02 (+0.04%) ▲|BKNG159.02-1.26 (-0.79%) ▼|BLK1,059.63-4.73 (-0.44%) ▼|BMY61.15+0.32 (+0.53%) ▲|BNY145.40+1.48 (+1.03%) ▲|BRK-B502.65+2.15 (+0.43%) ▲|C128.50+1.50 (+1.18%) ▲|CAT845.42+19.07 (+2.31%) ▲|CL84.26-0.27 (-0.32%) ▼|CMCSA21.57-0.13 (-0.60%) ▼|COF194.72+0.24 (+0.12%) ▲|COP126.75-0.31 (-0.24%) ▼|COST920.65+5.71 (+0.62%) ▲|CRM234.69-2.00 (-0.85%) ▼|CSCO112.20+3.86 (+3.56%) ▲|CVS86.46+1.26 (+1.48%) ▲|CVX206.69-0.41 (-0.20%) ▼|DE687.00+19.74 (+2.96%) ▲|DHR214.06+2.30 (+1.09%) ▲|DIS102.19+0.86 (+0.85%) ▲|DUK114.13+0.39 (+0.34%) ▲|EMR161.61+3.04 (+1.92%) ▲|FDX290.36+3.29 (+1.15%) ▲|GD330.09-2.63 (-0.79%) ▼|GE309.56-2.83 (-0.91%) ▼|GEV988.70+1.25 (+0.13%) ▲|GILD144.74-2.76 (-1.87%) ▼|GM78.27-1.04 (-1.31%) ▼|GOOG340.35+5.42 (+1.62%) ▲|GOOGL343.50+5.26 (+1.56%) ▲|GS902.56+5.89 (+0.66%) ▲|HD282.85+0.39 (+0.14%) ▲|HON213.99+0.19 (+0.09%) ▲|IBM222.64-2.98 (-1.32%) ▼|INTC119.33-0.67 (-0.56%) ▼|INTU281.08-1.70 (-0.60%) ▼|ISRG391.95-9.29 (-2.32%) ▼|JNJ256.03-2.63 (-1.02%) ▼|JPM332.38-0.80 (-0.24%) ▼|KO85.65-0.45 (-0.52%) ▼|LIN479.48+10.03 (+2.14%) ▲|LLY1,142.85-7.00 (-0.61%) ▼|LMT505.41-0.09 (-0.02%) ▼|LOW180.80-1.58 (-0.87%) ▼|LRCX347.49+7.39 (+2.17%) ▲|MA552.26+2.26 (+0.41%) ▲|MCD231.89+0.06 (+0.03%) ▲|MDLZ58.19+0.43 (+0.74%) ▲|MDT86.38-0.06 (-0.07%) ▼|META728.08+2.15 (+0.30%) ▲|MMM161.89-1.13 (-0.69%) ▼|MO67.35+0.40 (+0.60%) ▲|MRK144.30+0.49 (+0.34%) ▲|MS190.31+2.30 (+1.22%) ▲|MSFT517.53+4.73 (+0.92%) ▲|MU1,074.89-22.50 (-2.05%) ▼|NEE76.83+0.48 (+0.63%) ▲|NFLX67.06-0.79 (-1.16%) ▼|NKE33.87-1.28 (-3.64%) ▼|NOW134.38-3.38 (-2.45%) ▼|NVDA233.95+3.09 (+1.34%) ▲|ORCL142.30+4.23 (+3.06%) ▲|PEP125.89+0.29 (+0.23%) ▲|PFE27.80-0.32 (-1.14%) ▼|PG144.91+0.96 (+0.67%) ▲|PLTR188.75-1.29 (-0.68%) ▼|PM187.46+0.88 (+0.47%) ▲|QCOM184.87+2.78 (+1.53%) ▲|RTX184.68-0.33 (-0.18%) ▼|SBUX94.71-0.17 (-0.18%) ▼|SCHW96.70-1.67 (-1.70%) ▼|SO83.72+0.25 (+0.30%) ▲|SPG200.95+0.14 (+0.07%) ▲|T24.30+0.00 (+0.00%) ▲|TMO654.80+2.29 (+0.35%) ▲|TMUS163.64+1.91 (+1.18%) ▲|TSLA370.59+16.48 (+4.65%) ▲|TXN293.80+12.49 (+4.44%) ▲|UBER68.11+0.23 (+0.34%) ▲|UNH371.90+6.70 (+1.83%) ▲|UNP278.28+5.86 (+2.15%) ▲|UPS93.02-0.87 (-0.93%) ▼|USB57.51+0.15 (+0.26%) ▲|V360.66+0.81 (+0.23%) ▲|VZ45.92-0.06 (-0.13%) ▼|WFC80.45+0.20 (+0.25%) ▲|WMT104.26+0.00 (+0.00%) ▲|XOM164.01+0.19 (+0.12%) ▲|
23.2 C
New York
Saturday, October 3, 2026

globenewswire

Heimar hf.: Acquisition of Gróska Completed

The acquisition by Heimar hf. ("Heimar" or the "Company") of all shares in Gróska ehf. (“Gróska”) and Gróðurhúsið ehf. (“Gróðurhúsið”) (the “Transaction”), which was initially announced on 23 April this year, has now been completed. 

Heimar hf.: Kaup Heima á Grósku frágengin

Kaup Heima hf. („Heimar“ eða „félagið“) á öllu hlutafé Grósku ehf. („Gróska“) og Gróðurhússins ehf. („Gróðurhúsið“) („viðskiptin“), sem tilkynnt var um 23. apríl sl., eru nú frágengin.  

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

Alectra releases 2024 ESG and GRE&T Centre reports highlighting commitment to sustainability, community support and grid modernization

MISSISSAUGA, Ontario, June 13, 2025 (GLOBE NEWSWIRE) -- Alectra Inc. presents its 2024 Annual Environmental, Social and Governance (ESG) Report, ‘Discover the Possibilities’, showcasing significant progress toward its long-term sustainability goals while continuing to deliver reliable, affordable energy services to more than one million homes and businesses across Ontario.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTRE

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline.

Unibel : COMMUNIQUE DE PRESSE DU 13 JUIN 2025 RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE DE LA SOCIETE

COMMUNIQUE DE PRESSE DU 13 JUIN 2025
RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE DE LA SOCIETE

Channel Factory Announces Latest Move to Elevate North American Executive Leadership Team

Digital Advertising Sales Leader, Nico Greco, Promoted to Chief Revenue Officer, North America
Digital Advertising Sales Leader, Nico Greco, Promoted to Chief Revenue Officer, North America

Leverage Shares by Themes continues product expansion with a new single stock leveraged ETF, bringing investors an exciting opportunity to amplify exposure to Boeing...

GREENWICH, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- Leverage Shares by Themes, an issuer of innovative exchange-traded products, is excited to announce the launch of the Leverage Shares 2X long BA Daily ETF (ticker: BOEG), a new single stock leveraged ETF, available for trading starting June 13, 2025 on Nasdaq. The product is designed to equip investors to amplify returns (up and down) and dynamically participate in the performance of a leading transportation and aerospace company. The new ETF is tailored to target a 200% exposure to the daily performance of its underlying stock, Boeing Co. (BA), offering sophisticated traders and the retail investor an efficient tool to capitalize on market movements at an industry low management fee for single stock leveraged ETFs at .75%.

First Time Homeowners Finally Get A Break

New Federal GST Rebate is a Game Changer for First-Time Home Buyers

Regarding the investment in the share capital of UAB “Ateities ūkis”

In order to promote the production of raw milk in Lithuania, AB "Rokiškio sūris" has invested EUR 10 million in to the authorized capital of UAB "Ateities ūkis" by acquiring 29.67 per cent of the authorized capital. UAB "Ateities ūkis" is a company belonging to the Agrokoncernas group, one of the main activities of which is the production of raw milk. In the opinion of the management of AB Rokiškio sūris, this transaction is beneficial for the company, as it will ensure an increase in the production of high-quality raw milk in Lithuania. The Management is also confident that the transaction is financially secure and will not have a significant impact on the company's performance and financial situation.

Dėl investicijos į UAB „Ateities ūkis“ įstatinį kapitalą

AB „Rokiškio sūris“, siekdamas skatinti žaliavinio pieno gamybą Lietuvoje, investavo 10 mln. Eurų į UAB „Ateities ūkis“ įstatinį kapitalą, įsigydama 29,67 proc. įstatinio kapitalo. UAB „Ateities ūkis“ yra įmonė priklausanti Agrokoncernas grupei, kurios viena iš pagrindinių veiklų yra žaliavinio pieno gamyba. AB „Rokiškio sūris“ vadovybės nuomone šis sandoris yra naudingas bendrovei, kadangi bus užtikrintas kokybiško žaliavinio pieno gamybos padidėjimas Lietuvoje. Taip pat Vadovybė įsitikinusi, kad sandoris yra finansiškai saugus ir neturės reikšmingos įtakos bendrovės veiklos rezultatams bei finansinei padėčiai.

VNUE, Inc. Announces Change in Strategy & Direction

VNUE, Inc. Announces Change in Strategy & Direction

13171229 B.C. Ltd. and Launchit Solutions Inc. Announce Execution of Business Combination Agreement and Launchit’s Concurrent Financing

VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- 1317229 B.C. Ltd. (“131” or the “Company”) and Launchit Solutions Inc. (“Launchit”) are pleased to announce that the Company, Launchit and 1001240330 Ontario Inc. (“Subco”), a wholly-owned subsidiary of the Company, have entered into a business combination agreement dated June 12, 2025 (the “Business Combination Agreement”) pursuant to which the Company will acquire Launchit by way of a three-cornered amalgamation, which will result in the reverse takeover of 131 by Launchit (the “Proposed Transaction”). Upon completion of the Proposed Transaction, the Company will continue to carry on the business of Launchit (thereafter referred to as the “Resulting Issuer”).

- A word from our sponsors -

spot_img

Follow us